Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-20
2007-11-20
Solola, Taofiq (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S353000
Reexamination Certificate
active
10969440
ABSTRACT:
Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.
REFERENCES:
patent: 3823144 (1974-07-01), Schmitt et al.
patent: 4269990 (1981-05-01), May et al.
patent: 5977108 (1999-11-01), Kikuchi et al.
patent: 6140338 (2000-10-01), Naya et al.
patent: 6288103 (2001-09-01), Faull et al.
patent: 6316449 (2001-11-01), Bratton et al.
patent: 6329402 (2001-12-01), Kikuchi et al.
patent: 6342516 (2002-01-01), Umeda et al.
patent: 0 004 187 (1979-09-01), None
patent: 0 234 098 (1987-09-01), None
patent: 2 001 284 (1969-09-01), None
patent: 1 250 611 (1974-10-01), None
patent: 2-144546 (1990-06-01), None
patent: 9-255572 (1997-09-01), None
patent: 92/14710 (1992-09-01), None
patent: 97/24325 (1997-07-01), None
patent: 97/44329 (1997-11-01), None
patent: 98/02151 (1998-01-01), None
patent: 98/06703 (1998-02-01), None
patent: 98/27815 (1998-07-01), None
patent: 98/04554 (1999-05-01), None
patent: 99/40072 (1999-08-01), None
patent: 01/57003 (2001-08-01), None
patent: 01/57021 (2001-08-01), None
patent: 01/57044 (2001-08-01), None
Gong, et al, An antagonist of monocyte chemoattractant potein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model, PMID: 9207007 (1997).
Alam et al., “Increased MCP-1, RANTES, and MIP-1α in Bronchoalveolar Lavage Fluid of Allergic Asthmatic Patients,”Am J Respir Crit Care Med, 153:1398-1404. (1996).
Alcami et al., “Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein form Vaccinia Virus”,J Immunol, 160:624-633 (1998).
Antoniades et al., “Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis”,Proc Natl Acad Sci USA, 89:5371-5375 (1992).
Ajuebor et al., “ Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model”,Journal of Leukocyte Biology, vol. 63:108-116, Jan. 1998.
Baggiolini et al., “Human Chemokines; an update”, Annu rev Immunol (1997), pp. 15:675-705.
Baggiolini, Chemokines and Leukocyte Traffic, Nature vol. 392:9 pp. 565-568, (1998).
Boring et al., “Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis”.Nature, 394:894-897 (1998).
Bright et al., “Identification of a Non Peptidic Rantes Antagonist”,Bioorg Med Chem Lett, 8:771-774 (1998).
Campbell et al., “Monocyte Chemoattractant Protein-1 Mediates Cockroach Allergen-Induced Bronchial Hyperreactivityin Normal but Not CCR2-/-Mice: The Role of Mast Cells”,J Immunol, 163:2160-2167 (1999).
Luster, “Chemokines˜Chemotactic Cytokines That Mediate Inflammation”,The New England Journal of Medicine. pp. 436-445. Feb. 12, 1998.
Folkman and Shing, “Control of Angiogenesis by Heparin and Other Sulfated Polysaccharides”,Adv Exp Med Biol., 313:355-364 (1992).
Forbes et al., “CCR2B Receptor Antagonists: Conversion of a Weak HTS Hit to a Potent Lead Compound”,Bioorg Med Chem. Lett, 10:1803-1806 (2000).
36Gosling et al., “MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that over express human apo37lipoprotein B”,J Clin Invest, 103:773-778 (1999).
Gu et al., “Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoportein Receptor-Deficient Mice”,Mol Cell, 2:275-281 (1998).
Hesselgesser, “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,J. Biol Chem, 273: 15687-15692 (1998).
Hoogewerf et al., “Glycosaminoglycans Mediate Cell Surface Oligomerization of Chemokines”, Biochemistry 36:13570-13578, (1997).
Hosaka et al., “Expression of the Chemokine Superfamily in Rheumatoid Arthritis”,Clin Exp Immunol, 97:451-457. (1994).
Hsieh et al., “Immunotherapy Suppresses the Production of monocyte chemotactic and activating factor and augments the production of IL-8 in Children with Asthma”, JAllergy Clin Immunol, 98:580-587 (1996).
Kitano M. et al., “Synthesis and Biological Activity of N-(Aminoiminomethyl)-1H-Idoleca Rboxamide Inhibitors”, Chem and Pharm Bulletin, Pharmaceutical Society of Japan, vol. 47, No. 11, Nov. 1999, pp. 1538.
Koch et al., “Enhanced Production of Monocyte Chemoattractant Protein-1 in Rheumatoid Arthritis”,J Clin Invest, 90:772-779, (1992).
Kunkel et al., “The Role of Chemokines in Inflammatory Joint Disease”,J Leukocyte Biol, 59:6-12 (1996).
Kurashima et al., “Increase of Chemokine Levels in Sputum Precedes Exacerbation of Acute Asthma Attacks”,J Leukocyte Biol.59:313-316, ((1996).
Kuschert et al., “Glycosamineoglycans interact selectively with chemokines and moldulate receptor binding and cellular responses”,Biochemistry38:12959-12968, (1999).
Liang et al., “Identification and characterization of a potent, selective and orally active antagonist of the cc chemokine receptor-1”,The Journal of Biological Chemistry, vol. 25:19000-19008, Jun. 23, 2000.
McFadden and Kelvin, “New Strategies for Chemokine Inhibition and Modulation”,Biochem Pharmacol, 54:1271-1280 (1997).
Mirzadegan et al., “Identification of the binding site for a novel class of CCR2bcemokine receptor antagonists . . . ”, The American Society for Biochemistry and Molecular Biology, Inc., manuscript M000692200, (2000).
Moore et al., “Tumor angiogenesis is regulated by CXC chemokines”,J Lab Clin Med, 132:97-103 (1998.
Moore et al., “CXC Chemokine Modulation of angiogenesis . . . ”,J Investigative Medicine, vol. 46:113-120 (1998).
Murphy, :The Molecular Biology of Leukocyte Chemoattractant Receptors,Annu Rev Immun,12:593-633, (1994).
Nelken et al., “Monocyte Chemoattractant Protein-1 in Human Atheromatous Plaques”,J. Clin. Invest, 88:1121-1127 (1991).
Okada et al., “Synthesis and Antitumor Activities of Water-Soluble Benzoylphenylureas”,Chem Pharm Bull, 47:430-433. (1999).
Okada et al., “ Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas”,Chem Pharm Bull42:57-61, (1994).
Okada et al., “Synthesis and Antitumor Activities of Novel Benzoylphenylurea Derivatives”,Chem Pharm Bull, 39:2308-2315 (1991 ).
Proost et al., “The Role of Chemokines in Inflammation”,Int J Clin Lab Res, 26:211-223, (1996).
Robinson et al., “Chemokine expression in Rheumatoid Arthritis . . . ”,Clin Exp Innumol101:398-407 (1995).
Rollins, “Chemokines”,Blood, vol. 90 No. 3, pp. 909-928, Aug. 1, 1997.
Rousseau, Jean-Francois et al., Chemical Abstract, “Regioselective ortho-directed metalation and electrophilic substitution of indoleand indoling -5-(N-phenyl) carboxamides” retrieved from STN database accession No. 136:355126 XP002206081 abstract & Heterocycles 92001), 55(12), 2289-2304.
Rovin et al., “Chemotactic Factors and Renal Inflammation”,American Journal of Kidney Diseases, 31 1065-1084. Jun. 1998.
Rovin, “Chemokines as Therapeutic Targets in Renal Inflammation”, American Journal Kidney Diseases, 34: 761-767, Oct. 1999.
Rovin, “Chemokine blokade as a thearapy for renal disease”,Current Opinion in Nephrology and Hypertension, 13:225-232, (2000).
Rovin et al., “A Novel Polymorphism in the MCP-1 Gene Regulatory Region Than Influences MCP-1 Expression”,Biochemical and Biophysical Research Communciations, 259, pp. 34
Anuskiewicz Steven E.
Inagaki Hideaki
Ishiwata Yoshiro
Jomori Takahito
Kakigami Takuji
Foley & Lardner LLP
Sanwa Kagaku Kenkyusho Co.
Solola Taofiq
Telik, Inc.
LandOfFree
Antagonists of MCP-1 function and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of MCP-1 function and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of MCP-1 function and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807654